PARP1 and cholangiocarcinoma: By further optimizing USP1 inhibitors, adding GCN5 acetyltransferase blockade, and integrating standard chemotherapy or immunotherapy, the USP1-PARP1 co-targeting strategy could be translated into a precision second-line or maintenance therapy for advanced CCA within the next 5–10 years.